Alnylam Pharmaceuticals (ALNY) Non-Current Debt (2016 - 2021)

Alnylam Pharmaceuticals (ALNY) has 6 years of Non-Current Debt data on file, last reported at $675.7 million in Q4 2021.

• For the quarter ending Q4 2021, Non-Current Debt rose 253.25% year-over-year to $675.7 million; the trailing twelve-month figure through Dec 2021 stood at $675.7 million (up 253.25% YoY), and the FY2021 full-year result was $675.7 million, up 253.25% from the prior year.
• Non-Current Debt for Q4 2021 stood at $675.7 million, up from $191.3 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $675.7 million in Q4 2021 and bottomed at $30.0 million in Q4 2017.
• The 5-year median for Non-Current Debt is $30.0 million (2017), against an average of $127.2 million.
• The widest annual swing landed in 2017, when Non-Current Debt plunged 80.0%; it then surged 253.25% in 2021.
• A 5-year view of Non-Current Debt shows it stood at $30.0 million in 2017, then changed by 0.0% to $30.0 million in 2018, then changed by 0.0% to $30.0 million in 2019, then surged by 537.59% to $191.3 million in 2020, then soared by 253.25% to $675.7 million in 2021.
• The last three Non-Current Debt figures came in at $675.7 million (Q4 2021), $191.3 million (Q4 2020), and $30.0 million (Q2 2019), per Business Quant data.

Peer Comparison